Calidi Biotherapeutics, Inc. (CLDI) Misses Q2 EPS by 121c

Calidi Biotherapeutics, Inc. (NYSE: CLDI) reported Q2 EPS of ($1.40), $1.21 worse than the analyst estimate of ($0.19).

For earnings history and earnings-related data on Calidi Biotherapeutics, Inc. (CLDI) click here.

You May Also Be Interested In

• Silver Lake In Talks To Buy Workday, Sources Say - Reuters
• Active options: NVDA TSLA SPCX MU SMCI INTC AAPL IREN AMZN
• Jefferies on Yeti Holdings Inc. (YETI): 'Reiterate Buy on Today's Weakness'